ANDA 211090, held by Biocon Pharma. Pemetrexed Disodium.
As of Nov 15, 2026, ANDA 211090 (Pemetrexed Disodium), held by Biocon Pharma, was first approved by FDA on May 25, 2022, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 25, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Pemetrexed DisodiumEQ 1GM BASE/VIAL ยท powder;intravenous | Pemetrexed Disodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
